AbbVie: Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or the "Company") (NASDAQ:CERE) for violations of the federal securities laws on behalf of investors who: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive (the "Class Period") and thus were damaged by Defendants' violations of Section 10(b) of the Exchange Act (the "Fraud Claim Class"); (b) held shares of Cerevel as of the January 8, 2024 record date ("Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by Defendants' violations of Section 14(a) of the Exchange Act (the "Proxy Claim Class"); and (c) sold shares ...Full story available on Benzinga.com